Drug intelligence / Profile preview

Xylonix Hygiene Nasal Spray

Development stage: Unknown
Lead developer: IP Holdings
Modality: Small Molecules
Administration: Intranasal

Overview

Xylonix (specifically Xylonix Hygiene Nasal Spray) is a topical antiseptic formulation developed by Xylonix IP Holdings for the prevention and management of upper respiratory infections, including COVID-19. The product utilizes a proprietary povidone-iodine (PVD-Iodine) formulation delivered via intranasal spray. Its mechanism of action involves the topical inactivation of infectious pathogens within the nasal cavity, thereby reducing viral and bacterial load at the primary site of entry and potentially preventing systemic infection or transmission. The product is currently approved and marketed as a hygiene solution for infectious disease prevention.

Brand names: XylonixXylonix Hygiene Nasal Spray
Other names: PVD-Iodine nasal spray

Beyond the preview

Go deeper on Xylonix Hygiene Nasal Spray.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xylonix Hygiene Nasal Spray.

Explore the full profile